Literature DB >> 20021421

Inhibitors of the Ubiquitin-Proteasome System and the cell death machinery: How many pathways are activated?

Claudio Brancolini1.   

Abstract

Over the past decade, the promising results of UPSIs (UPS inhibitors) in eliciting apoptosis in various cancer cells, and the approval of the first UPSI (Bortezomib/Velcade/PS-341) for the treatment of multiple myeloma have raised interest in assessing the death program activated upon proteasomal blockage. Several reports indicate that UPSIs stimulate apoptosis in malignant cells by operating at multiple levels, possibly by inducing different types of cellular stress. Normally cellular stress signals converge on the core elements of the apoptotic machinery to trigger the cellular demise. In addition to eliciting multiple stresses, UPSIs can directly operate on the core elements of the apoptotic machinery to control their abundance. Alterations in the relative levels of anti and pro-apoptotic factors can render cancer cells more prone to die in response to other anti-cancer treatments. Aim of the present review is to discuss those core elements of the apoptotic machinery that are under the control of the UPS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 20021421     DOI: 10.2174/1874467210801010024

Source DB:  PubMed          Journal:  Curr Mol Pharmacol        ISSN: 1874-4672            Impact factor:   3.339


  11 in total

1.  Proteasome inhibition can impair caspase-8 activation upon submaximal stimulation of apoptotic tumor necrosis factor-related apoptosis inducing ligand (TRAIL) signaling.

Authors:  Maike A Laussmann; Egle Passante; Christian T Hellwig; Bartlomiej Tomiczek; Lorna Flanagan; Jochen H M Prehn; Heinrich J Huber; Markus Rehm
Journal:  J Biol Chem       Date:  2012-03-09       Impact factor: 5.157

2.  Circulating extracellular proteasome in the cerebrospinal fluid: a study on concentration and proteolytic activity.

Authors:  Oliver Mueller; Timur Anlasik; Jonas Wiedemann; Jan Thomassen; Jeremias Wohlschlaeger; Vincent Hagel; Kathy Keyvani; Isabel Schwieger; Burkhardt Dahlmann; Ulrich Sure; Stephan Urs Sixt
Journal:  J Mol Neurosci       Date:  2011-09-01       Impact factor: 3.444

3.  Isopeptidases in anticancer therapy: looking for inhibitors.

Authors:  Andrea Sgorbissa; Harish Potu; Claudio Brancolini
Journal:  Am J Transl Res       Date:  2010-05-10       Impact factor: 4.060

4.  Proteasome inhibition by quercetin triggers macroautophagy and blocks mTOR activity.

Authors:  Anja K Klappan; Stefanie Hones; Ioannis Mylonas; Ansgar Brüning
Journal:  Histochem Cell Biol       Date:  2011-10-13       Impact factor: 4.304

5.  The Isopeptidase Inhibitor G5 Triggers a Caspase-independent Necrotic Death in Cells Resistant to Apoptosis: A COMPARATIVE STUDY WITH THE PROTEASOME INHIBITOR BORTEZOMIB.

Authors:  Alessandra Fontanini; Carmela Foti; Harish Potu; Enrico Crivellato; Roberta Maestro; Paolo Bernardi; Francesca Demarchi; Claudio Brancolini
Journal:  J Biol Chem       Date:  2009-01-12       Impact factor: 5.157

Review 6.  The Role of the Ubiquitin Proteasome System in Glioma: Analysis Emphasizing the Main Molecular Players and Therapeutic Strategies Identified in Glioblastoma Multiforme.

Authors:  Semer Maksoud
Journal:  Mol Neurobiol       Date:  2021-03-04       Impact factor: 5.682

7.  A new combination strategy to enhance apoptosis in cancer cells by using nanoparticles as biocompatible drug delivery carriers.

Authors:  Ertan Kucuksayan; Fatih Bozkurt; Mustafa Tahsin Yilmaz; Aslinur Sircan-Kucuksayan; Aysegul Hanikoglu; Tomris Ozben
Journal:  Sci Rep       Date:  2021-06-22       Impact factor: 4.379

8.  BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells.

Authors:  Zhu Yuan; Fang Wang; Zhiwei Zhao; Xinyu Zhao; Ji Qiu; Chunlai Nie; Yuquan Wei
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

Review 9.  Modulation of apoptosis sensitivity through the interplay with autophagic and proteasomal degradation pathways.

Authors:  M E Delgado; L Dyck; M A Laussmann; M Rehm
Journal:  Cell Death Dis       Date:  2014-01-23       Impact factor: 8.469

Review 10.  Counteracting PINK/Parkin Deficiency in the Activation of Mitophagy: A Potential Therapeutic Intervention for Parkinson's Disease.

Authors:  Alice Nardin; Emilie Schrepfer; Elena Ziviani
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.